McVicar says Flex Pharma will have clinical trials reading out in the Q1 as well as in Q3 in ALS, multiple sclerosis, and Charcot-Marie-Tooth disease. Flex Pharma will report Q4 and full year 2017 results on March 7, 2018.
Flex Pharma to prove technology can prevent cramping in ALS
Quick facts: Flex Pharma
Price: - -
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE